Journal article
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Abstract
BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.
METHODS: In this randomised, double-blind, parallel-group, placebo-controlled, phase 3 study (CALIMA) …
Authors
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S
Journal
The Lancet, Vol. 388, No. 10056, pp. 2128–2141
Publisher
Elsevier
Publication Date
October 2016
DOI
10.1016/s0140-6736(16)31322-8
ISSN
0140-6736
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, InhalationAdrenal Cortex HormonesAdultAgedAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaChildDisease ProgressionDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleForced Expiratory VolumeHumansInjections, SubcutaneousMaleMiddle AgedPulmonary EosinophiliaReceptors, Interleukin-5